Biotech80
🚀 $ANNX BIG CATALYSTS AHEAD!
Annexon could be approaching a transformational period.
🔥 ARCHER II: Month-15 DMC assessment approaching. Positive efficacy and safety signals could be a major turning point for vonaprument.
🔥 TANRUPRUBART: European regulatory review underway, with US BLA submission targeted for Q4 2026. Huge potential in Guillain-Barré syndrome.
🔥 ANX1502: Another potential value driver with proof-of-concept data ahead.
💰 $209.2M cash and investments at June 2026, plus credit-facility access and management guidance for runway into 2028.
📊 31.6M shares reported short as of October 15. Next short-interest update November 10.
Multiple clinical programmes. Multiple catalysts. Significant potential.
If the data deliver, the market could be forced to reassess Annexon’s value.
The next few months could be pivotal. Don’t lose sight of what is building here!
🚀 $ANNX
7
